Literature DB >> 28490031

A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6).

N Timmerby1, J H Andersen, S Søndergaard, S D Østergaard, Per Bech.   

Abstract

BACKGROUND: In a study aimed at identifying the items carrying information regarding the global severity of depression, the 6-item Hamilton Depression Rating Scale (HAM-D6) was derived from the original 17-item version of the scale (HAM-D17). Since then, the HAM-D6 has been used in a wide range of clinical studies. We now provide a systematic review of the clinimetric properties of HAM-D6 in comparison with those of HAM-D17 and the Montgomery Asberg Depression Rating Scale (MADRS).
METHODS: We conducted a systematic search of the literature in PubMed, PsycInfo, and EMBASE databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Studies reporting data on the clinimetric validity of the HAM-D6 and either the HAM-D17 or MADRS in non-psychotic unipolar or bipolar depression were included in the synthesis.
RESULTS: The search identified 681 unique records, of which 51 articles met the inclusion criteria. According to the published literature, HAM-D6 has proven to be superior to both HAM-D17 and MADRS in terms of scalability (each item contains unique information regarding syndrome severity), transferability (scalability is constant over time and irrespective of sex, age, and depressive subtypes), and responsiveness (sensitivity to change in severity during treatment).
CONCLUSIONS: According to the published literature, the clinimetric properties of HAM-D6 are superior to those of both the HAM-D17 and MADRS. Since the validity of HAM-D6 has been demonstrated in both research and clinical practice, using the scale more consistently would facilitate translation of results from one setting to the other.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  6-Item Hamilton Depression Rating Scale; Antidepressant medication; Clinimetrics; Depression rating scale; Systematic literature review

Mesh:

Year:  2017        PMID: 28490031     DOI: 10.1159/000457131

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  14 in total

1.  Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly: Data from the pride study.

Authors:  Søren D Østergaard; Maria S Speed; Charles H Kellner; Martina Mueller; Shawn M McClintock; Mustafa M Husain; Georgios Petrides; William V McCall; Sarah H Lisanby
Journal:  J Affect Disord       Date:  2020-05-23       Impact factor: 4.839

2.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

3.  Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression.

Authors:  Anders Jorgensen; Kristin Köhler-Forsberg; Trine Henriksen; Allan Weimann; Ivan Brandslund; Christina Ellervik; Henrik E Poulsen; Gitte Moos Knudsen; Vibe G Frokjaer; Martin B Jorgensen
Journal:  Transl Psychiatry       Date:  2022-05-16       Impact factor: 7.989

4.  Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol.

Authors:  Kristin Köhler-Forsberg; Anders Jorgensen; Vibeke H Dam; Dea Siggaard Stenbæk; Patrick M Fisher; Cheng-Teng Ip; Melanie Ganz; Henrik Enghusen Poulsen; Annamaria Giraldi; Brice Ozenne; Martin Balslev Jørgensen; Gitte Moos Knudsen; Vibe Gedsoe Frokjaer
Journal:  Front Psychiatry       Date:  2020-07-23       Impact factor: 4.157

5.  Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.

Authors:  Sophie Juul; Faiza Siddiqui; Marija Barbateskovic; Caroline Kamp Jørgensen; Michael Pascal Hengartner; Irving Kirsch; Christian Gluud; Janus Christian Jakobsen
Journal:  Syst Rev       Date:  2021-05-25

6.  The challenge of measurement in psychiatry: the lifetime accomplishments of Per Bech (1942-2018).

Authors:  Marcelo P Fleck; Danilo Carrozzino; Giovanni A Fava
Journal:  Braz J Psychiatry       Date:  2019-10-17       Impact factor: 2.697

7.  Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study.

Authors:  Erik Roj Larsen; Rasmus W Licht; René Ernst Nielsen; Annette Lolk; Bille Borck; Claus Sørensen; Ellen Margrethe Christensen; Gustav Bizik; Janus Ravn; Klaus Martiny; Maj Vinberg; Odeta Jankuviené; Pernille Blenker Jørgensen; Poul Videbech; Per Bech
Journal:  Eur Psychiatry       Date:  2020-02-18       Impact factor: 5.361

Review 8.  Can an Integrated Science Approach to Precision Medicine Research Improve Lithium Treatment in Bipolar Disorders?

Authors:  Jan Scott; Bruno Etain; Frank Bellivier
Journal:  Front Psychiatry       Date:  2018-08-21       Impact factor: 4.157

9.  Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.

Authors:  Boadie W Dunlop; Sagar V Parikh; Anthony J Rothschild; Michael E Thase; Charles DeBattista; Charles R Conway; Brent P Forester; Francis M Mondimore; Richard C Shelton; Matthew Macaluso; Jennifer Logan; Paul Traxler; James Li; Holly Johnson; John F Greden
Journal:  BMC Psychiatry       Date:  2019-12-27       Impact factor: 3.630

10.  Different cytokine patterns associate with melancholia severity among inpatients with major depressive disorder.

Authors:  Lucas Primo de Carvalho Alves; Neusa Sica da Rocha
Journal:  Ther Adv Psychopharmacol       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.